⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HCM News
HUTCHMED (China) Limited American Depositary Shares
HUTCHMED Reports 2026 Interim Results
globenewswire.com
HCM
LLY
AZN
TMDX
HUTCHMED to Announce 2026 Half-Year Financial Results
globenewswire.com
HCM
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
globenewswire.com
HCM
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
globenewswire.com
HCM
AI
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
globenewswire.com
HCM
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
globenewswire.com
HCM
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
globenewswire.com
HCM
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
globenewswire.com
HCM
HUTCHMED Reports 2025 Full Year Results and Business Updates
globenewswire.com
HCM
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
globenewswire.com
HCM